In a 33‑week pregnant patient with esophageal varices, how should propranolol therapy be managed (continue, adjust dose, or initiate)?

Management of Propranolol for Esophageal Varices in Pregnancy

Continue propranolol throughout pregnancy for both primary and secondary prophylaxis of variceal bleeding, as the benefits of preventing life-threatening hemorrhage far outweigh the theoretical risks of fetal growth restriction. 1

Guideline-Based Recommendation

The 2023 EASL guidelines provide a strong recommendation (Level of Evidence 2) that beta-blockers should either be initiated or continued during pregnancy for primary or secondary prophylaxis of variceal bleeding, provided there are no contraindications. 1 This represents the highest-quality, most recent guidance available and directly addresses your clinical scenario.

Rationale for Continuation

• Maternal mortality from variceal bleeding (up to 18-50% in acute hemorrhage) vastly exceeds any fetal risk from propranolol exposure. 1 The physiological changes of pregnancy—including inferior vena cava compression after 20 weeks and peak intravascular volume expansion at 28-32 weeks—significantly increase portal pressure and variceal bleeding risk. 1, 2

• Propranolol reduces portal pressure by decreasing cardiac output and splanchnic blood flow, thereby preventing variceal rupture. 3 Historical trials in non-pregnant cirrhotic patients demonstrate that propranolol reduces first variceal hemorrhage from 22% to 4% compared to placebo. 4

Carvedilol vs. Propranolol Consideration

• If initiating beta-blockade during pregnancy, carvedilol may be preferable to propranolol because a cardiovascular study showed carvedilol was not associated with fetal growth restriction whereas propranolol carried this risk. 1 However, if the patient is already stable on propranolol, switching agents mid-pregnancy introduces unnecessary risk of inadequate portal pressure control during the transition period.

• For a patient already on propranolol at 33 weeks gestation, continue the current regimen rather than switching to carvedilol, as you are past the critical period of organogenesis and approaching delivery. 1

Dosing and Monitoring

• Maintain the dose that achieves a 25% reduction in resting heart rate or reduces heart rate to <55 beats/min, which correlates with adequate portal pressure reduction. 4 The FDA label indicates typical doses range from 80-160 mg daily for portal hypertension indications. 5

• Pregnancy increases drug clearance for many medications, potentially requiring dose adjustments upward to maintain therapeutic effect. 6 Monitor heart rate at each prenatal visit and adjust propranolol dose if resting heart rate rises above target.

• Screen for gestational diabetes, as beta-blockers may mask hypoglycemic symptoms (tachycardia, tremor) in insulin-dependent patients. 5

Complementary Endoscopic Management

• If screening endoscopy was not performed within 1 year prior to conception, it should have been done in the second trimester. 1 At 33 weeks, endoscopy should only be performed for urgent indications (active bleeding or high clinical suspicion of high-risk varices not previously documented). 1

• High-risk varices (large size or red wale signs) require endoscopic band ligation in addition to propranolol. 1 The combination of EVL plus propranolol reduces bleeding risk more than propranolol alone (4% vs. 13% cumulative probability). 7

Delivery Planning

• Plan vaginal delivery with a shortened second stage using assisted delivery (forceps or vacuum) to minimize Valsalva maneuvers that spike portal pressure. 1, 8 Reserve cesarean section only for standard obstetric indications. 1

• Position the patient in left lateral tilt or left lateral decubitus during labor and any procedures to prevent aortocaval compression by the gravid uterus, which further elevates portal pressure. 1, 8, 2

• Ensure immediate availability of blood products (packed red cells, platelets, fresh-frozen plasma) given the 5-45% risk of postpartum hemorrhage in cirrhotic patients. 1, 8

Critical Pitfalls to Avoid

• Do NOT discontinue propranolol during pregnancy based on outdated concerns about fetal effects; current high-quality guidelines explicitly recommend continuation. 1

• Do NOT abruptly stop propranolol even postpartum, as withdrawal can precipitate rebound hypertension and increased bleeding risk. 5 If discontinuation is ever planned, taper gradually over several weeks. 5

• Do NOT use terlipressin if acute variceal bleeding occurs, as its potent vasoconstriction causes uterine ischemia, placental abruption, and fetal loss. 1, 9 Octreotide (50 µg IV bolus then 50 µg/hour infusion) is the only acceptable vasoactive agent in pregnancy. 9

• Do NOT position the patient supine after 20 weeks gestation during any procedure or monitoring, as aortocaval compression reduces placental perfusion and worsens portal hypertension. 1, 8, 2

Postpartum Management

• Continue propranolol indefinitely postpartum for ongoing variceal prophylaxis, as portal hypertension persists despite resolution of pregnancy-related hemodynamic changes. 1

• Schedule follow-up endoscopy 6-12 weeks postpartum to reassess variceal status, as pregnancy-related portal pressure elevations typically resolve after delivery. 8